ABSTRACT A simple method for determining pyrimidine 5'-nucleotidase (P5N) activity in whole blood has been developed, inhibiting the plasma activity for UMP-hydrolysis by concanavalin (Con A). Con A specifically inhibits the activity of plasma 5'-nucleotidase (SN) but does not affect erythrocyte P5N activity. The anticoagulant EDTA partially inhibits SN activity but slightly activates P5N. P5N activity determined by the present method with heparinised blood and Con A was comparable with that by the method reported previously and correlated well with blood lead concentrations. The mean value and SD for P5N activity in normal subjects (n = 72) not exposed to lead are 16-2 and 2 5 pmole/h/g Hb, respectively. The present method can eliminate not only the isolation step of RBC but also Hb determination, the activity being expressed as pmole/h/l blood or RBC. Thus the procedures are so simplified that the assay may be used as a routine test for mass screening of lead exposure.
Pyrimidine 5'-nucleotidase (P5N, EC 3.1.3.5) in the red cell cytosol catalyses the hydrolytic dephosphorylation of pyrimidine S'-monophosphates but is ineffective on purine nucleotidase. The presence of P5N was first reported by Valentine et al in 1974 in their description of haemolytic anaemia.' Hereditary P5N deficiency results in a non-spherocytic haemolytic anaemia in which the erythrocytes contain extremely high concentrations of pyrimidine nucleotides and show pronounced basophilic stippling. Erythrocyte P5N activity is also known to decline in lead poisoning.2" The measurement of the enzyme activity has a diagnostic value in these disorders.
The conventional method for determining P5N activity is based on the liberation of inorganic phosphorus from pyrimidine 5'-nucleotides and requires time consuming and complicated procedures, limiting its application in the clinical laboratory. We have previously developed a rapid and sensitive method for P5N, in which the product (uridine) is separated from the substrate (UMP) and red cell constituents by means of high performance liquid chromatography (HPLC). Because the amount ofendogenous uridine is non-detectable and the intensity of the absorption of uridine is high at 254 nm, the need to dialyse the sample is eliminated and the incubation time is Accepted 6 April 1987 shortened. Nevertheless, the method still requires washed erythrocytes as the enzyme source, since serum 5'-nucleotidase (SN) non-specifically hydrolyses S'-nucleotide to release inorganic phosphate at neutral condition. SN activity is known to be increased in hepatobiliary disease and serves as a diagnostic tool for the disorder.7"8 In the present paper we describe P5N assay in whole blood, inhibiting SN activity by a specific inhibitor, concanavalin A (Con A).9'
Materials and methods
Venous blood, treated with EDTA-2K or heparin as anticoagulants, was obtained from lead workers and from normal subjects with no history of exposure to lead. The lead workers were employed in secondary smelters, glass factories, and printing offices. Erythrocytes were separated from plasma, washed twice with a 10-fold volume of saline (0 9% NaCI), and then suspended in saline (about 50% suspension; RBC/ saline). For the determination of P5N or 5N activity whole blood, or both, RBC/saline or plasma were used for the enzyme sources. P5N (and/or SN) activity was determined by the method previously reported with some modifications56 as follows: the enzyme solution was prepared by diluting 50 pl of blood, RBC/saline, or plasma to 550 pl with distilled water. Commercially available UMP-Na (Sigma Chemical Co, Saint Louis, USA) was used as the substrate without purification 420 Determination ofpyrimidine 5'-nucleotidase (P5N) activity in whole blood as an index of lead exposure instead of buffered substrate as in the original method. 5 The standard assay mixture contained 550 u1 of enzyme solution, 100 p1 of 02M Tris-HCI buffer (pH 7-7) containing 75 mM MgCl2, 50 p1 of Con A (type IV, Sigma Chemical Co, Saint Louis, USA) solution (20 g/ 1), and 50 p1 of 50 mM UMP-Na. To determine the P5N activity without Con A, distilled water was added to the mixture instead of Con A solution. The reaction was started by adding substrate at 37°C. After 60 minutes the reaction was terminated by placing the tubes in boiling water for three minutes. Then 2 25 ml of distilled water were added to the mixture and agitated. After centrifugation, the resulting supernatant was used for the HPLC analysis. A Shimadzu liquid chromatograph (Shimadzu, Kyoto, Japan) consisting of a pump (LC-3A), an automatic sample injector (SIL-2A), a column oven (CTO-2A), a variable wavelength spectrophotometer (SPD-1), and an integrator (C-RIA) was used. Flow rate, oven temperature, and detector wavelength were set at 1 0 ml/ min, 40°C, and 254 nm, respectively. The column (150 x 4 mm) used was packed with reversed phase (ODS) silica. The mobile phase was 5% methanol containing 5 mM KH2PO4 and 0 2 mM 1-decanesulphonic acid. Samples were cooled at 4°C during a series of analyses and IO pl were automatically injected at seven minute intervals. The unit (u) of P5N activity was expressed as pmole/h/g Hb, pmole/h/l RBC, or pmole/h/l blood, and that of plasma 5N as ymole/min/l. Serum 5N activity (pmole/min/l) in some subjects was also determined by the method of Belfield et al." Hb concentrations in RBC/saline or blood were determined using a haemoglobin counter (TOA Medical Electronic Co, Tokyo, Japan), which directly measured Hb concentrations spectrophotometrically as cyanmethaemoglobin. Blood lead concentrations (Pb-B) were determined by the method previously reported. 12 Results Figure 1 shows the effect of increasing amounts of inhibitor Con A on hydrolysis of UMP by blood from a normal subject whose SN activity in serum was umole/min/l. Zero to 5 mg of Con A are added to the reaction mixtures to produce final concentrations of 0 to 6-67 mg/I of Con A. The activity of heparinised blood declines in a linear fashion as the amount of inhibitor increases up to 0 5 mg but no further decline is observed when the amount of the inhibitor exceeds 0-5 mg. It appears that the difference between the activity in the presence and absence of Con A corresponds to the action of SN in plasma, and that the residual activity with Con A exceeding 0-5 mg represents the hydrolysis of UMP by erythrocyte ConA (mg) enzyme (P5N). The effect of Con A on UMPhydrolysis of blood treated with EDTA differs considerably from that of heparinised blood. Even without addition of Con A, hydrolysis of UMP by blood treated with EDTA is weaker than that by heparinised blood. The activity of EDTA treated blood is further reduced with the addition of Con A. The residual activity, however, is slightly higher than that of heparinised blood. To discover the effects of EDTA or Con A, or both, on the enzymic hydrolysis of UMP by blood, plasma or erythrocytes from heparinised blood were examined separately. RBC/saline from normal heparinised blood was used as the enzyme source with or without treatment of EDTA, which was carried out by incubating RBC/saline with EDTA-2K (8 mM) for 20 hours at 4°C. Con A (I mg) was added to the reaction mixture. Results were the mean ± SD of triplicate determinations. Figure 2a shows that the data with RBC from EDTA treated blood (RE -) are similar to those of the method (RH-) reported previously, indicating that the activating effect of EDTA on the erythrocyte enzyme is eliminated by washing erythrocytes with saline. It is also confirmed that Con A has no effect on the erythrocyte enzyme (fig 2b) . The activities obtained with blood treated with EDTA (WE -)or heparin (WH -) are higher (27 2% or 21 8%, respectively) than those using the previous method (RH-, figs 2c and d). It appears that the differences between activity with whole blood and with erythrocytes are due mainly to the plasma action (5N) of hydrolysis. The amount of EDTA used as anticoagulant seems to be not sufficient totally to inhibit the activity ofplasma (fig 2d) . The concentration should not be so high as in the experiments reported in table 1. Activities determined with heparinised blood and Con A (WH +) agree well with those of the earlier method (RH-, fig  2e) , whereas data from EDTA treated blood and Con A (WE +) are slightly higher (RH-, fig 2f) . The slightly raised activity in EDTA treated blood (WE +) is due to the weak activation oferythrocyte enzyme by EDTA. Based on these findings, it appears that Con A is useful as a differential inhibitor of enzymic hydrolysis of UMP by plasma SN and erythrocyte P5N.
To evaluate the method for determining P5N activity with whole blood and Con A, we adopted it to the larger group of lead workers (n = 37). Figure 3 shows the relations between Pb-B and P5N activity determined with whole blood in the presence or absence of Con A. When P5N activity is determined with whole blood in the presence of Con A (figs 3a, c), correlation coefficients of Pb-B v log P5N are improved by comparison with those in the absence of inhibitor (figs 3b, d). In the presence of Con A the activities with EDTA treated blood (fig 3c) are slightly higher (about 10%) than those with heparinised blood (fig 3a) . Thus in the present study the method with heparinised blood and Con A (WH + ) was selected for determining P5N activity in lead workers. The activity may be expressed in imole/h/l blood or RBC, omitting the measurement of Hb. In the expression of pmole/h/l RBC, however, Hct determination is necessary. In 83 lead workers we compared the expression of the three types of unit with regard to the relation of Pb-B v P5N activity (fig 4) . A strong negative correlation was observed between Pb-B and log P5N activity expressed in pmole/h/l RBC (r = -0-91) and in imole/h/l blood (r = -0 88) and when expressed in conventional units (r = -0-91). The three units may be converted using the equations given in table 5.
In the present method with heparinised blood and 
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Con A the reference value was determined in a control group of non-exposed men (n = 72). The arithmetic mean and SD of P5N activity were 16-2 and 2 5 ,mole/ h/g Hb, respectively. The age of the subjects ranged between 19 and 55 (mean ± SD, 344 ± 60). No significant relation was found between age (x) and P5N activity (y) (y = 00192x + 15 5, r = 009). Within assay and between assay CVs are shown in table 6, indicating that the precision of the present method is sufficiently accurate to detect decreased activity in subjects exposed to lead. Sakai, Araki, Ushio Table 5 Relations among P5N activities expressed in three types ofunit 
